lobbying_activities: 3239642

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3239642	ec1641e6-47ed-4b96-9371-5ea3be5c49a9	Q3	ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)	1466	ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)	2024	third_quarter	MED	* On July 7, ADLM joined with other healthcare providers in supporting a resolution to employ the Congressional Review Act as it pertains to the FDAs Proposed Rule, Docket No. FDA-2023-N-2177, Medical Devices: Laboratory Developed Tests. * On September 5, ADLM wrote to House and Senate leaders providing survey results indicating the clinical laboratories will have problems complying with the FDA final rule regulating LDTs. * On August 15 and September 4, ADLM initiated grassroots campaigns urging House and Senate members to support future legislative efforts to revoke the FDA LDT final rule. * On September 10th, ADLM participating in Rare Disease Congress Caucus outlining concern about FDA LDT final rule.	HOUSE OF REPRESENTATIVES,SENATE		60000	0	0	2024-10-16T10:32:59-04:00